EDARAVONE: A NEW APPROACH TO TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

РУСТАМОВА ЧАРОС РУСТАМ КИЗИ, ЯКУБОВА МАРХАМАТ МИРАКРАМОВНА, КАРШИБАЕВА НАРГИЗА ИБРОХИМ КИЗИ

Журнал неврологии и нейрохирургических исследований / Journal of Neurology and Neurosurgical Research · 2021-yil

Annotatsiya

 Amyotrophic lateral sclerosis (ALS) is a fatal progressive disease of the central nervous system with damage to the upper and lower motor neurons and leading to severe disability and death 3-5 years after its debut (1).Until 2017, riluzole was the only approved medication for patients with ALS, offering a limited survival benefit of about 3–5 months.(2) In 2017, the FDA approved another drug for the treatment of ALS - edaravone (trade names: radicut, radicava, aron, ceravon).(3) The drug acts as a strong antioxidant, destroying lipid peroxidation products (LPOP) and hydroxyl radicals. As with riluzole, the exact mechanism of action of edaravone is not clear. The drug is thought to mitigate oxidative damage to neurons and glia (accessory cells in nerve tissue) that are at risk in ALS. In a phase III clinical study of the drug in Japan, 137 patients with an early stage of ALS development participated. Edaravone has been shown to be effective in suppressing the deterioration of motor function in these patients. Although in the USA edaravone was approved for the treatment of all patients with ALS, it was recommended to use it in the early stages of the disease, within 2 years from the date of debut in patients with a forced vital capacity of more than 80%.( 4). There are no data on the effectiveness of edaravone in the wider population of ALS patients. A study of the effectiveness of this drug with an assessment of survival is ongoing. In view of the above, the development of new approaches to ALS therapy remains an urgent problem. 

Maqola ma’lumotlari
MualliflarРУСТАМОВА ЧАРОС РУСТАМ КИЗИ, ЯКУБОВА МАРХАМАТ МИРАКРАМОВНА, КАРШИБАЕВА НАРГИЗА ИБРОХИМ КИЗИ
JurnalЖурнал неврологии и нейрохирургических исследований / Journal of Neurology and Neurosurgical Research
Nashr sanasi2021-11-04
TilIngliz

Kalit so‘zlar

боковой амиотрофический склероз, эдаравон, окислительное повреждение, механизм действия, Amyotrophic lateral sclerosis, edaravone, oxidative damage, mechanism of action, Yon amiotrofik skleroz, edaravon, oksidlovchi shikastlanish, ta'sir mexanizmi

Ilmiy soha

Журнал неврологии и нейрохирургических исследований / Journal of Neurology and Neurosurgical Research jurnalidan boshqa maqolalar

Журнал неврологии и нейрохирургических исследований / Journal of Neurology and Neurosurgical Research — barcha maqolalar